Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer
Authors:
- Valesca P. RetèlVRValesca P. Retèl
- Manuela A. JooreMJManuela A. Joore
- Michael KnauerMKMichael Knauer
- Sabine C. LinnSLSabine C. Linn
- Michael HauptmannMHMichael Hauptmann
- Wim H. van HartenWHWim H. van Harten
- 1 May 2010
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 46 (8) , 1382-1391
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009Annals of Oncology, 2009
- Constructive Technology Assessment (CTA) as a tool in Coverage with Evidence Development: The case of the 70-gene prognosis signature for breast cancer diagnosticsInternational Journal of Technology Assessment in Health Care, 2009
- Validation of 70-gene prognosis signature in node-negative breast cancerBreast Cancer Research and Treatment, 2008
- The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation studyBreast Cancer Research and Treatment, 2008
- Gene expression profiling: Does it add predictive accuracy to clinical characteristics in cancer prognosis?European Journal of Cancer, 2007
- Impact of a 21‐gene RT‐PCR assay on treatment decisions in early‐stage breast cancerCancer, 2007
- Recent Developments in Decision-Analytic Modelling for Economic EvaluationPharmacoEconomics, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002